John Hemphill, MD
Neurology with Special Qualifications in Child Neurology · Savannah, GANPI 1285672329
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $1,491,364 of the $2,023,518 with a category attached, or 73.7%. It is spread thinly across 60 manufacturers, the largest accounting for just 15.5%. Among neurology with special qualifications in child neurology clinicians in GA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 3,564 payments — averaging $567.77 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Eisai Inc.$313K
- Amgen$309K
- EMD Serono, Inc.$265K
- AbbVie$207K
- AstraZeneca$173K
- Sanofi$113K
- plus $643K from 54 others
Across 531 payments — averaging $5588.64 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Novartis$870K
- AbbVie$777K
- Sanofi$538K
- Adamas Pharmaceuticals, Inc.$126K
- Roche Products Limited$120K
- TG Therapeutics, Inc.$105K
- plus $431K from 13 others
What the payments were for
- Consulting fees$178,0259%
- Speaking & faculty fees$1,491,36474%
- Travel & lodging$284,34114%
- Food & beverage$68,9833%
- Education$8040%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Leqembi$265,072
- Mavenclad$236,107
- UPLIZNA$185,085
- BOTOX$115,022
- AIMOVIG$91,558
- ULTOMIRIS$90,569
- ZEPOSIA$81,147
- UBRELVY$79,140
- BRIUMVI$65,005
- OCREVUS$54,926
- VYVGART$48,345
- Fycompa$43,477
- VYVGART HYTRULO$39,544
- LEMTRADA$36,609
- VYEPTI$34,971
- Vumerity$31,265
- NURTEC ODT$29,256
- TYSABRI$28,214
- AUBAGIO$27,556
- TECFIDERA$24,973
How this compares
$2,023,518 in reported general payments places this provider in the 95th percentile of 41 neurology with special qualifications in child neurology providers in Georgia.
See all neurology with special qualifications in child neurology providers in Georgia →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MavencladCladribine | 11 | $692,095 |
| VumerityDiroximel Fumarate | 72 | $639,876 |
| GammaplexImmun Glob G(Igg)/Gly/Iga 0-50 | 17 | $452,064 |
| AustedoDeutetrabenazine | 21 | $209,451 |
| OctagamImmun Globg(Igg)/Malt/Iga Ov50 | 23 | $164,716 |
| Nurtec OdtRimegepant Sulfate | 96 | $156,158 |
| Kesimpta PenOfatumumab | 18 | $153,746 |
| BriviactBrivaracetam | 86 | $139,989 |
| Aimovig AutoinjectorErenumab-Aooe | 140 | $121,928 |
| UbrelvyUbrogepant | 70 | $74,560 |
| QuliptaAtogepant | 68 | $74,396 |
| AptiomEslicarbazepine Acetate | 38 | $70,129 |
| Oxtellar XrOxcarbazepine | 23 | $62,950 |
| QutenzaCapsaicin/Skin Cleanser | 16 | $56,646 |
| FycompaPerampanel | 39 | $48,248 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| EMD Serono, Inc.Mavenclad | $265,000 | $692,09511 claims |
| BiogenVumerity | $100,609 | $639,87672 claims |
| PfizerOctagam, Nurtec Odt | $7,480 | $320,875119 claims |
| Teva Pharmaceuticals USA, Inc.Austedo | $40,096 | $209,45121 claims |
| AbbVieUbrelvy, Qulipta | $206,604 | $148,956138 claims |
| UCB, Inc.Briviact | $16,977 | $139,98986 claims |
| Sunovion Pharmaceuticals Inc.Aptiom | $665 | $70,12938 claims |
| Supernus Pharmaceuticals, Inc.Oxtellar Xr | $519 | $62,95023 claims |
| Eisai Inc.Fycompa | $312,697 | $48,24839 claims |
| Avanir Pharmaceuticals, Inc.Nuedexta | $137 | $35,86724 claims |
| Otsuka America Pharmaceutical, Inc.Rexulti | $150 | $35,15322 claims |
| SK Life Science, Inc.Xcopri | $5,516 | $31,69327 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 41 neurology with special qualifications in child neurology providers in Georgia.
Other neurology with special qualifications in child neurology in Savannah
- Katherine MoretzSavannah$144K
- Eric PearlmanSavannah$298
- Chaouki KhouryAtlanta$978K
- Yong ParkAugusta$78K
- Daniel TarquinioGainesville$50K
- Han PhanAtlanta$44K
- Raymond ChengAtlanta$40K
- Sonam BhallaAtlanta$23K
- Cherise FrazierAtlanta$9K
- Enrique FernandezBrunswick$8K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.